**Programme**

**29th October**

15.45-16.15. Registration and congress documentation

16.15. Opening

Maria C. Barberá [Fundación Aecosan], Jesús San Miguel, Ignacio Melero, José Luis Pérez Gracia, Pedro Berrando

16.30 – 17.00. Keynote Lecture
Chair: Pedro Berrando. CIMA. Ignacio Melero. CIMA y CLIN

Future of cancer immunotherapy: Enhancement or normalization?

Lisping Chen. Yale. USA

17.00 – 18.00. Break

18.00 – 20.40. Exploiting tumor antigenicity
Chair: Juanjo Lasarte. CIMA. Pablo Sarobe. CIMA

18.00. The Yin and Yang of Cancer Immunotherapy Combinations
Daniel Chen. BioTechne, USA

18.40. Targeting ideal Antigens for Cancer Immunotherapy
Oskar Tuuci. BioTechne, Germany

19.20. Cancer immunotherapy beyond PD-1: novel pathways and combinations
Andrea van Elstas. ADURO, Netherlands

20.00. Radiotherapy and immunotherapy shoulder to shoulder into the fray
Silvia Ferrenti. Cornell. USA

**30th October**

09.00 – 10.00. Title: Immunotherapy development: industrial view and pipelines [I]
Chair: José Luis Pérez Gracia. CUN, Felipe Calvo. Hospital Gregorio Marañón. Madrid

09.00. Novel Drug Combinations for Cancer Immunotherapy
Nils Landberg. BMS. USA

09.30. Medimmune cancer immunotherapy approach
Bahija Zallal. Medimmune. USA

09.40. MSD cancer immunotherapy approach
David Kaufman. MSD. USA

10.00 – 10.40. Round table discussion

10.40 – 11.00. Coffee break

11.00 – 12.20. Immunotherapy development: industrial view and pipelines [II]
Chair: Luis Paz-Ares. Hospital Universitario Dexeus de Barcelona. Spain

11.00. Advances in CAR T cell therapy: C019 Therapy and Beyond
Jennifer Brudvig. Novartis. USA

11.20. Building a Next-Generation Immuno-Oncology Pipeline in a Competitive Space: Perspectives from a “New Kid on the Block”
Llucsi Rodríguez. Merck Serono. USA

11.40. A therapeutic strategy to target cold tumors
Eric Bange. Boehringer Ingelheim. Germany

12.00. The silly Immunoncology pipeline: enabling rational combinations
Michael Ketta. Lilly, USA

12.20 – 12.40. Round table discussion

12.45 – 14.00. Lunch break

14.00-14.30. Keynote lecture
Chair: Ignacio Melero. CIMA y CLIN, Ruth Vera. Hospital de Navarra

Clinical development of lung cancer immunotherapy
Luis Paz-Ares. Hospital Universitario Dexeus de Barcelona. Spain

14.30 – 16.30. Immunotherapy based on evidence
Chair: Ruben Pio. CIMA, Mario Rodriguez. CIMA y CLIN

14.30. Targeting immune modulation at the tumour site
Sergio Quezada. UCL, UK

15.10. Anti-cancer immune therapy of melanoma
María Sanjuán. Yale, USA

15.50. Exploiting radiotherapy in immunotherapy combinations
Timothy Edging. The University of Manchester. UK

16.30 – 16.50. Coffee break

16.50 – 18.50. Immunotherapy biomarkers, working in the tissue
Chair: Dolores Lozano. CUN, Miguel Gómez. CUN

16.50. Understanding the tumor immune composition using multilevel quantitative approaches
Kurt Schaper. Yale, USA

17.30. Diagnostics in the era of Cancer Immunotherapy
Prof. Hedeberg. Boche Genentech, USA

18.10. Role of Immunotherapy in Hodgkin and non-Hodgkin Lymphomas
Scott J. Rodig. Brigham and Women’s Hospital, USA

**31st October**

09.00 – 10.00. TNFR costimulation in action
Chair: David Escors. Reversamo. Spain, Fernando Pastor. CIMA

09.00. CD40 stimulation: the rules of a complex game
Ann White. UCL Colbath. UK

09.40. Moving forward CD137-based immunotherapies
Ignacio Melero. CIMA y CLIN

10.20 GTR and 4-1BB in chronic viral infection: implications for cancer therapy
Tania Watts. University of Toronto. Canada

11.00 – 11.30. Coffee break

11.30 – 14.10. Genetics and genetic intervention for better immunotherapies
Chair: Cristian Smerdou. CIMA, Rubén Hernández Alcoceba. CIMA

11.30. Identification of immunoreactive microsatellite stable (MSS) colorectal cancer for potential immune interventions
Nicolás Lázaro. Johns Hopkins, USA

12.10. Deconstructing the T cell Receptor Signaling nanomachine
Bibhsoo Alyann. CBM, Spain

12.50. Viruses and IFNγ in immunotherapy
Pedro Berrando. CIMA

13.30. Viral gene therapies
Ramón Alemany. VCN, Spain

14.10 – 15.30. Lunch break

15.30 – 17.40. Exploiting new tools to improve immunotherapy
Chair: Susanne Impey. CUN, Ignacio Gómez. CUN

15.30. Complement in cancer immunotherapy
Rubén Pio. CIMA. Spain

16.10. Patient-derived tumor models for immunotherapy development
Miguel Sammado. Yale. USA

17.00. Identifying T cells specific against cancer
Aleina Gros. Vall d’Hebron, Spain
International Symposium:
“Trailblazing in cancer immunotherapy”
OCTOBER, 29th–31st

Fundación Ramón Areces

VENUE
Modern art museum. University of Navarra. Pamplona, Spain

SYMPOSIUM COORDINATORS
Dr. Ignacio Melero
Dr. Pedro Berraondo
Dr. Jose Luis Pérez Gracia

ORGANIZERS
Fundación para la Investigación Médica Aplicada
Clínica Universidad de Navarra

CONTACT
simposioareces@unav.es

REGISTRATIONS
http://simposioareces2017.viajesarga.com